Resource Summary Report

Generated by RRID on Jul 8, 2024

CD19 (D4V4B) XP® Rabbit mAb

RRID:AB_2800152
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 90176, RRID:AB_2800152)

Antibody Information

URL: http://antibodyregistry.org/AB_2800152

Proper Citation: (Cell Signaling Technology Cat# 90176, RRID:AB_2800152)

Target Antigen: CD19

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-Bond, IHC-P

Antibody Name: CD19 (D4V4B) XP® Rabbit mAb

Description: This monoclonal targets CD19

Target Organism: h, m

Clone ID: Clone D4V4B

Antibody ID: AB_2800152

Vendor: Cell Signaling Technology

Catalog Number: 90176

Record Creation Time: 20231110T032759+0000

Record Last Update: 20240530T212320+0000

Ratings and Alerts

No rating or validation information has been found for CD19 (D4V4B) XP® Rabbit mAb.

No alerts have been found for CD19 (D4V4B) XP® Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell reports. Medicine, 5(2), 101397.

Zuo T, et al. (2023) Macrophage-Derived Cathepsin S Remodels the Extracellular Matrix to Promote Liver Fibrogenesis. Gastroenterology, 165(3), 746.

Liu Z, et al. (2023) Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer cell, 41(1), 181.

Martinez-Ordoñez A, et al. (2023) Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer. Cancer cell, 41(2), 252.

Chang YW, et al. (2023) A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8+ T cells. Cell reports. Medicine, 4(8), 101154.

Cox EM, et al. (2023) AKT activity orchestrates marginal zone B cell development in mice and humans. Cell reports, 42(4), 112378.

Galaz J, et al. (2023) Host-microbiome interactions in distinct subsets of preterm labor and birth. iScience, 26(12), 108341.

Xu Y, et al. (2022) Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers. Cell reports, 40(9), 111295.

Chaurio RA, et al. (2022) TGF-?-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity, 55(1), 115.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell reports. Medicine, 3(9), 100744.

Pascal LE, et al. (2021) Prostate-Specific Deletion of Cdh1 Induces Murine Prostatic Inflammation and Bladder Overactivity. Endocrinology, 162(1).

Peran I, et al. (2021) Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Gastroenterology, 160(4), 1359.

Wieland A, et al. (2021) Defining HPV-specific B cell responses in patients with head and neck cancer. Nature, 597(7875), 274.

Rodriguez AB, et al. (2021) Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell reports, 36(3), 109422.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular cell, 81(10), 2094.

Zhang Y, et al. (2021) Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer cell, 39(12), 1578.

Lazarian G, et al. (2021) A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer cell, 39(3), 380.

Jeffries MA, et al. (2020) Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis. ASN neuro, 12, 1759091420971916.